Funding rounds
20 company funding rounds disclosed in the monthly RiseFinder box for November 2026.
- Period
- Monthly
- Window
- 30d
- Rows
- 20
- Data through
- November 2026
01/Monthly box
20 entries
01On its website, the company describes its work as “Angle Health is an AI-enabled health insurance plan delivering comprehensive employee health benefits. We help employers offer group health insurance that supports their teams while…”. Its SEC Form D filed on 2026-10-29 reports US$591,524,799 in securities sold, with a first sale date of 2026-10-15. The amount reflects the securities sales disclosed by the company in this offering at the filing date; it is separate from the offering's target amount and from measures of product traction.
SEC Form D
Open source ↗$592m
$592m of $600m target
On its website, the company describes its work as “Click Therapeutics is redefining modern medicine with patient-centric digital treatments. Operating at the intersection of biology and technology, Click combines neuroscience with the power of…”. Its SEC Form D filed on 2026-10-01 reports US$49,999,999 in securities sold, with a first sale date of 2026-04-07. The amount reflects the securities sales disclosed by the company in this offering at the filing date; it is separate from the offering's target amount and from measures of product traction.
SEC Form D
Open source ↗$50.0m
$50.0m of $50.0m target
On its website, the company describes its work as “Expressable’s model of care also focuses on the most important part of improving children’s speech and language skills: the involvement of their parent or caregiver.…”. Its SEC Form D filed on 2026-10-15 reports US$25,499,994 in securities sold, with a first sale date of 2026-09-30. The amount reflects the securities sales disclosed by the company in this offering at the filing date; it is separate from the offering's target amount and from measures of product traction.
SEC Form D
Open source ↗$25.5m
$25.5m of $35.5m target
On its website, the company describes its work as “Finwave brings the power of Moore’s Law and scaling to RF GaN devices. Finwave’s patented approach for linearizing both power amplifiers (PAs) and low noise…”. Its SEC Form D filed on 2026-10-08 reports US$15,532,045 in securities sold, with a first sale date of 2026-08-25. The amount reflects the securities sales disclosed by the company in this offering at the filing date; it is separate from the offering's target amount and from measures of product traction.
SEC Form D
Open source ↗$15.5m
$15.5m of $21.2m target
On its website, the company describes its work as “Founded by a group of Carnegie Mellon alumni including a pediatric surgeon, PECA Labs is revolutionizing cardiovascular implantable devices with a polymer platform and a…”. Its SEC Form D filed on 2026-10-09 reports US$12,789,342 in securities sold, with a first sale date of 2026-09-30. The amount reflects the securities sales disclosed by the company in this offering at the filing date; it is separate from the offering's target amount and from measures of product traction.
SEC Form D
Open source ↗$12.8m
$12.8m of $21.5m target
On its website, the company describes its work as “Best-in-class technology. Tissue-free detection. Adela is advancing the field of epigenomics to transform how cancer is detected and monitored. By leveraging proprietary methylome analysis technology…”. Its SEC Form D filed on 2026-10-19 reports US$12,000,000 in securities sold, with a first sale date of 2026-10-02. The amount reflects the securities sales disclosed by the company in this offering at the filing date; it is separate from the offering's target amount and from measures of product traction.
SEC Form D
Open source ↗$12.0m
$12.0m of $12.0m target
On its website, the company describes its work as “URXR One · Spatial Display Glasses Light is Light 6DoF room-scale tracking, hand-gesture recognition, and high-fidelity video see-through, all in a 93-gram frame. Stay Updated…”. Its SEC Form D filed on 2026-10-15 reports US$9,999,990 in securities sold, with a first sale date of 2026-10-08. The amount reflects the securities sales disclosed by the company in this offering at the filing date; it is separate from the offering's target amount and from measures of product traction.
SEC Form D
Open source ↗$10.0m
$10.0m of $10.0m target
On its website, the company describes its work as “About Tempest Therapeutics Developing differentiated solutions for the next generation of in vivo CAR-T therapies Tempest Therapeutics is a clinical-stage biotechnology company focused on pioneering…”. Its SEC Form D filed on 2026-10-14 reports US$7,500,000 in securities sold, with a first sale date of 2026-09-15. The amount reflects the securities sales disclosed by the company in this offering at the filing date; it is separate from the offering's target amount and from measures of product traction.
SEC Form D
Open source ↗$7.5m
$7.5m of $7.5m target
On its website, the company describes its work as “Amira is 100% bilingual in English and Spanish and connects assessment, instruction and tutoring, so a district strategy and what happens in a classroom are…”. Its SEC Form D filed on 2026-10-09 reports US$4,999,995 in securities sold, with a first sale date of 2026-09-28. The amount reflects the securities sales disclosed by the company in this offering at the filing date; it is separate from the offering's target amount and from measures of product traction.
SEC Form D
Open source ↗$5.0m
$5.0m of $14.0m target
On its website, the company describes its work as “ORBIT ELECTRONICS GROUP Delivering leading-edge operator interfaces that stand up to the most severe battlefield, shipboard and airborne conditions. Go to the Orbit Electronics Group…”. Its SEC Form D filed on 2026-10-07 reports US$4,075,000 in securities sold, with a first sale date of 2026-09-23. The amount reflects the securities sales disclosed by the company in this offering at the filing date; it is separate from the offering's target amount and from measures of product traction.
SEC Form D
Open source ↗$4.1m
$4.1m of $4.1m target
On its website, the company describes its work as “PreciseBreast® uses OncoIntelligence TM , our proprietary AI-platform, to combine AI-grade with key clinical factors to produce an OncoIntelligence Score TM . PreciseBreast®, clinically…”. Its SEC Form D filed on 2026-10-07 reports US$3,699,998 in securities sold, with a first sale date of 2026-09-23. The amount reflects the securities sales disclosed by the company in this offering at the filing date; it is separate from the offering's target amount and from measures of product traction.
SEC Form D
Open source ↗$3.7m
$3.7m of $3.7m target
On its website, the company describes its work as “The CI acceleration platform used by teams that ship fast Detect, quarantine, and eliminate flaky tests Any language, any test runner, any CI provider. →…”. Its SEC Form D filed on 2026-10-07 reports US$2,825,940 in securities sold, with a first sale date of 2026-09-24. The amount reflects the securities sales disclosed by the company in this offering at the filing date; it is separate from the offering's target amount and from measures of product traction.
SEC Form D
Open source ↗$2.8m
$2.8m of $6.8m target
On its website, the company describes its work as “Cala is the intelligent heat pump water heater that customizes water heating for each home, each day. Proudly Designed And Assembled In The USA Why…”. Its SEC Form D filed on 2026-10-27 reports US$2,550,000 in securities sold, with a first sale date of 2026-10-13. The amount reflects the securities sales disclosed by the company in this offering at the filing date; it is separate from the offering's target amount and from measures of product traction.
SEC Form D
Open source ↗$2.5m
$2.5m of $3.0m target
On its website, the company describes its work as “Forward-Deployed AI Data Engineering Factored engineers embed in your environment, work across your stack, and drive critical engineering through production. Meet An Expert Start Building…”. Its SEC Form D filed on 2026-10-14 reports US$2,499,999 in securities sold, with a first sale date of 2026-09-24. The amount reflects the securities sales disclosed by the company in this offering at the filing date; it is separate from the offering's target amount and from measures of product traction.
SEC Form D
Open source ↗$2.5m
$2.5m of $2.5m target
On its website, the company describes its work as “The way for African businesses to make payments Send and receive money across the globe. Now available for both businesses and individuals in Cameroon, Nigeria,…”. Its SEC Form D filed on 2026-10-21 reports US$2,000,001 in securities sold, with a first sale date of 2026-10-15. The amount reflects the securities sales disclosed by the company in this offering at the filing date; it is separate from the offering's target amount and from measures of product traction.
SEC Form D
Open source ↗$2.0m
$2.0m of $2.0m target
On its website, the company describes its work as “OncoSmart is our AI-powered, digital transformation platform that optimizes and simplifies the complexities of community cancer clinic scheduling and nurse assignment operations. OncoSmart integrates with…”. Its SEC Form D filed on 2026-10-02 reports US$1,999,999 in securities sold, with a first sale date of 2026-10-01. The amount reflects the securities sales disclosed by the company in this offering at the filing date; it is separate from the offering's target amount and from measures of product traction.
SEC Form D
Open source ↗$2.0m
$2.0m of $2.0m target
On its website, the company describes its work as “The only whole-member intelligence solution that reveals your members' full story - clinical, social, and environmental - and shows you exactly what to do about…”. Its SEC Form D filed on 2026-10-02 reports US$1,551,300 in securities sold, with a first sale date of 2026-09-22. The amount reflects the securities sales disclosed by the company in this offering at the filing date; it is separate from the offering's target amount and from measures of product traction.
SEC Form D
Open source ↗$1.6m
$1.6m of $2.5m target
On its website, the company describes its work as “iPill.Tech | The Future of Medication Technology Products Proactive Care iPill™ Dispenser iPill™ App Solutions MAT/MOUD Opioid Treatment Justice Systems Chronic Pain Investor Relations About…”. Its SEC Form D filed on 2026-10-13 reports US$1,291,364 in securities sold, with a first sale date of 2026-10-01. The amount reflects the securities sales disclosed by the company in this offering at the filing date; it is separate from the offering's target amount and from measures of product traction.
SEC Form D
Open source ↗$1.3m
$1.3m of $1.5m target
On its website, the company describes its work as “Revivent Therapy is an investigational cardiac remodeling technique performed by a cardiothoracic surgeon under general anesthesia. It is designed to treat patients with heart failure…”. Its SEC Form D filed on 2026-10-08 reports US$1,200,000 in securities sold, with a first sale date of 2026-09-29. The amount reflects the securities sales disclosed by the company in this offering at the filing date; it is separate from the offering's target amount and from measures of product traction.
SEC Form D
Open source ↗$1.2m
$1.2m of $3.0m target
On its website, the company describes its work as “We walk working class families in Toledo, Akron, Warren, and Pittsburgh along a coached pathway from renting to owning, in real partnership. Begin Your Journey…”. Its SEC Form D filed on 2026-10-19 reports US$750,000 in securities sold, with a first sale date of 2026-10-06. The amount reflects the securities sales disclosed by the company in this offering at the filing date; it is separate from the offering's target amount and from measures of product traction.
SEC Form D
Open source ↗$750k
$750k of $1.3m target
This dated edition is generated from the reviewed RiseFinder export. Movement figures retain their original source, period and direction.
02/Get email updates
Join the list
Get early signals on the websites, apps, repositories and startups gaining momentum. Join the list for Risefinder email briefings.
By subscribing, you ask us to store your email and send Risefinder updates. You can unsubscribe at any time. Privacy.
Want a sample first? Read past daily emails.